HORSHAM, Pa.--(BUSINESS WIRE)--Acurian, Inc., a leading, full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD, announced today that Todd Albin, MBA, CCRP, has assumed the newly created position of senior director, site enrollment optimization.
Albin will manage Acurian’s longstanding site services department and its relatively newer field-based enrollment optimization representatives. According to Roger Smith, senior vice president of operations, Acurian’s appointment of Albin will enable sites to fully maximize the revenue and enrollment benefits from Acurian’s centralized patient recruitment efforts.
“Todd brings practical and management experience at the site level, which will help sharpen the support sites receive from us when managing potential study candidates from referral to randomization,” said Smith. “Trial candidates often have a short window of patience and interest once referred to a site, and Todd will improve on our site processes and communications to enhance sites’ conversion of those referrals. This will lead to increased revenue for sites and accelerated enrollment for sponsors.”
Albin said, “I’m pleased to join an organization that recognizes the role and importance of clinical research sites within the context of centralized patient recruitment. I’m equally emboldened by the challenge of helping take Acurian’s outstanding reputation to the next level by cultivating a culture of customer service and relationship management in the investigator and coordinator community.”
Albin obtained his bachelor of business from the University of Miami and his master of business administration from Florida International University. Prior to joining Acurian, he held a variety of clinical research positions at stand-alone sites, large site management organizations, and at higher education institutions.
About Acurian
Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time.
About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Acurian’s service offerings and expertise, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
